Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Ubiquitin carboxyl-terminal hydrolase 43 (USP43) is a member of the ubiquitin-specific protease family of deubiquitinating enzymes. It recognizes and hydrolyzes peptide bonds at the C-terminal glycine of ubiquitin, thereby generating monoubiquitin from polyubiquitin chains and processing ubiquitinated substrates. USP43 plays a key role in regulating the hypoxic response by associating with hypoxia-inducible factor 1-alpha (HIF-1α), facilitating its nuclear accumulation and the expression of HIF-1 target genes in a hypoxia- and phosphorylation-dependent manner. Mechanistically, USP43 associates with 14-3-3 proteins to support HIF-1α signaling, and while its enzymatic function as a DUB contributes, some non-catalytic functions are also observed. Additionally, USP43 is implicated in metastasis, where it is upregulated in a Ca_v2.2/calcium–NFAT2 axis, promoting invadopodia formation, extracellular matrix degradation, and tumor cell invasion through stabilization of cortactin in breast cancer. While no therapeutics directly targeting USP43 are currently described, its roles in hypoxia signaling and cancer metastasis make it a molecule of interest for future therapeutic development.
Deubiquitination of substrate proteins, Regulation of nuclear accumulation and chromatin association of HIF-1α (not solely dependent on enzymatic deubiquitination activity but also on protein–protein interactions with 14-3-3 proteins)
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ubiquitin carboxyl-terminal hydrolase 43 (USP43).